The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of
the experimental drug, entinostat, in women with breast cancer and men and women with
non-small cell lung cancer. The safety and tolerability of entinostat will also be evaluated
when entinostat is given by itself as well as with the approved drugs, exemestane (Aromasin®)
or erlotinib (Tarceva®). A biomarker (chemical "marker" in the blood/tissue that may be
related to your response to the study drug) will also be tested.